Physician profile
Sandy D Kotiah
NPI 1104035971
$247,003.48
in general payments reported to CMS, 2019-2025
85 companies · $62K in 2025
The $62K reported for 2025 was more than what 96% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104K · 2020: $22K · 2021: $17K · 2022: $11K · 2023: $11K · 2024: $20K · 2025: $62K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $40K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $18K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Travel and Lodging: $11K · Food and Beverage: $9,014 · Long Term Medical Supply Or Device Loan: $1,280 · Grant: $350 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $39,822.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $18,375.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,234.00 |
| Travel and Lodging | $10,988.03 |
| Food and Beverage | $9,013.90 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Grant | $350.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $72,957.05 | 2019-2024 | Nplate, Lumakras, Xgeva |
| Exelixis INC. | $38,621.43 | 2019-2025 | Cabometyx |
| Ipsen Biopharmaceuticals, INC | $36,541.44 | 2019-2024 | Onivyde, Somatuline Depot |
| E.R. Squibb & Sons, L.L.C. | $25,920.14 | 2019-2025 | Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $20,577.68 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12,824.38 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $11,178.89 | 2019-2025 | Imfinzi, Calquence, Lynparza |
| Lexicon Pharmaceuticals, INC. | $7,137.82 | 2020 | |
| Lilly USA, LLC | $3,616.59 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Sun Pharmaceutical Industries INC. | $2,836.00 | 2020 | |
| Rigel Pharmaceuticals, INC. | $2,545.69 | 2019-2024 | Tavalisse, Rezlidhia |
| Genzyme Corporation | $2,345.48 | 2019-2025 | |
| Advanced Accelerator Applications | $2,077.81 | 2019-2021 | |
| Incyte Corporation | $693.75 | 2019-2025 | Pemazyre, Jakafi, Pemazyre |
| Pfizer INC. | $631.07 | 2019-2025 |
Show all 84 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $478.09 | 2019-2025 | |
| Genentech USA, INC. | $424.84 | 2019-2025 | Venclexta, Itovebi, Phesgo |
| Gilead Sciences, INC. | $397.79 | 2019-2025 | Trodelvy |
| Merck Sharp & Dohme LLC | $366.55 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $294.24 | 2019-2025 | Rybrevant, Tecvayli, Talvey |
| Glaxosmithkline, LLC. | $254.03 | 2020-2025 | Jemperli, Zejula, Ojjaara |
| Daiichi Sankyo INC. | $253.95 | 2019-2025 | Enhertu, Injectafer |
| Seagen INC. | $241.61 | 2019-2025 | Adcetris, Tukysa |
| Intera Oncology, INC | $228.15 | 2024 | Intera |
| Jazz Pharmaceuticals INC. | $219.30 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $199.71 | 2019-2023 | Ultomiris |
| Pharmaessentia USA Corporation | $189.17 | 2022-2025 | Besremi |
| Eisai INC. | $178.77 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $169.83 | 2022-2024 | Iclusig |
| Celgene Corporation | $145.93 | 2019-2025 | Reblozyl, Pomalyst |
| Taiho Oncology, INC. | $140.65 | 2022-2025 | |
| Astellas Pharma US INC | $140.36 | 2020-2024 | Xtandi, Padcev |
| Pharmacyclics LLC, An Abbvie Company | $140.30 | 2022-2023 | Imbruvica, Epkinly |
| Tersera Therapeutics LLC | $138.03 | 2019-2025 | Xermelo, Zoladex |
| Bayer Healthcare Pharmaceuticals INC. | $128.55 | 2019-2025 | |
| Kite Pharma, INC. | $114.30 | 2020-2025 | Yescarta |
| Emd Serono, INC. | $111.92 | 2019-2020 | |
| Beigene USA, INC. | $95.83 | 2022-2024 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $86.61 | 2021-2025 | Libtayo |
| Sobi, INC | $85.83 | 2024-2025 | |
| Mirati Therapeutics, INC. | $80.57 | 2023-2024 | Krazati |
| Puma Biotechnology, INC. | $72.29 | 2019-2024 | Nerlynx |
| Ethicon US, LLC | $68.90 | 2022 | |
| Array Biopharma INC | $64.28 | 2019-2020 | |
| Genmab U.S., INC. | $52.19 | 2024-2025 | Epkinly |
| Tesaro, INC. | $50.54 | 2019 | |
| Morphosys, US INC. | $49.09 | 2023-2024 | Monjuvi |
| Pharmacosmos Therapeutics INC. | $46.80 | 2024-2025 | Monoferric |
| Helsinn Therapeutics (U.S.), INC. | $40.32 | 2019-2021 | |
| Aveo Pharmaceuticals, INC. | $39.30 | 2025 | |
| Foundation Medicine, INC. | $35.46 | 2019-2023 | Foundationone Cdx |
| Clovis Oncology, INC. | $32.16 | 2020 | |
| Servier Pharmaceuticals LLC | $31.91 | 2025 | |
| Syndax Pharmaceuticals, INC. | $30.79 | 2025 | |
| Menarini Silicon Biosystems, INC. | $26.63 | 2025 | |
| Amag Pharmaceuticals, INC. | $26.16 | 2019 | |
| G1 Therapeutics, INC. | $23.92 | 2022 | |
| Blueprint Medicines Corporation | $23.73 | 2024 | Ayvakit |
| Janssen Scientific Affairs, LLC | $23.62 | 2019 | |
| Myovant Sciences INC. | $23.32 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $23.14 | 2024 | Sancuso |
| Stemline Therapeutics INC. | $23.09 | 2025 | Orserdu |
| Geron Corporation | $22.58 | 2025 | Rytelo |
| Immunogen, INC. | $22.51 | 2023 | Elahere |
| Grifols USA, LLC | $21.57 | 2022 | |
| Corcept Therapeutics | $20.49 | 2025 | Korlym |
| Apellis Pharmaceuticals, INC. | $20.40 | 2024 | Empaveli |
| Recordati_rare_diseases_inc. | $20.36 | 2023 | Sylvant |
| Shield Therapeutics INC | $20.24 | 2024 | |
| Caris Mpi, INC. | $19.26 | 2025 | Mi Cancer Seek |
| Amarin Pharma, INC. | $17.75 | 2019 | |
| Dova Pharmaceuticals | $17.74 | 2019 | |
| Deciphera Pharmaceuticals INC. | $17.61 | 2025 | Qinlock, Romvimza |
| Shionogi INC | $17.11 | 2019 | |
| Alnylam Pharmaceuticals INC. | $16.71 | 2025 | Givlaari |
| Verastem, INC. | $16.18 | 2019 | |
| Digestive Care, INC. | $15.61 | 2022 | |
| Shire North American Group INC | $15.48 | 2019 | |
| Portola Pharmaceuticals, LLC | $15.45 | 2019 | |
| Janssen Pharmaceuticals, INC | $15.30 | 2023 | Xarelto |
| Telix Pharmaceuticals | $14.69 | 2024 | Illuccix |
| Acadia Pharmaceuticals INC | $13.44 | 2019 | |
| Clinigen, INC. | $13.20 | 2020 | |
| Bio Products Laboratory USA, INC. | $12.03 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandy Kotiah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.